OpenLegislation

Annex I

United Kingdom

Original text. Later amendments are not shown.

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:

Table 1
Short acting beta agonist bronchodilators
CountrySalbutamolTerbutalineFenoterolOrciprenalineReproterolCarbuterolHexoprenalinePirbuterolClenbuterolBitolterolProcaterol
AustriaXXXXXXXXXXX
BelgiumXXXXXXXXXXX
CyprusXXXXXXXXXXX
Czech RepublicXXXXXXXXXXX
DenmarkX
EstoniaXXXXXXXXXXX
FinlandXXXXXXXXXXX
FranceXXXXXXXXXXX
GermanyXXXXXXXXXXX
GreeceXXXXXXXXXXX
HungaryXXXXXXXXXXX
IrelandXXXXXXXXXXX
ItalyXXXXXXXXXXX
LatviaXXXXXXXXXXX
LithuaniaXXXXXXXXXXX
LuxembourgXXXXXXXXXXX
MaltaXXXXXXXXXXX
NetherlandsXXXXXXXXXXX
PolandX
PortugalXXXXXXXXXXX
NorwayXXXXXXXXXXX
SlovakiaXXXXXXXXXXX
SloveniaXXXXXXXXXXX
SpainXXXXXXXXXXX
SwedenXXXXXXXXXXX
United KingdomX
Table 2
Inhaled steroids
CountryBeclomethasoneDexamethasoneFlunisolideFluticasoneBudesonideTriamcinolone
AustriaXXXXXX
BelgiumXXXXXX
Cyprus
Czech RepublicXXXXXX
DenmarkXX
EstoniaXXXXXX
FinlandXX
FranceXX
GermanyXXXXXX
Greece
HungaryXXXXXX
IrelandXX
ItalyXXXXXX
LatviaXXXXXX
LithuaniaXXXXXX
LuxembourgXXXXXX
MaltaXX
Poland
PortugalXXX
The NetherlandsXXXXXX
Norway
SlovakiaXXXXXX
SloveniaXXXXXX
SpainXX
SwedenXX
United KingdomX
Table 3
Non steroidal anti inflammatories
CountryCromoglicic acidNedrocromil
AustriaXX
BelgiumXX
CyprusXX
Czech RepublicXX
DenmarkXX
EstoniaXX
FinlandXX
FranceXX
GermanyXX
GreeceXX
HungaryX
Ireland
ItalyXX
LatviaXX
LithuaniaXX
LuxembourgX
MaltaXX
Poland
PortugalX
The NetherlandsXX
Norway
SlovakiaXX
SloveniaXX
SpainX
SwedenXX
United Kingdom
Table 4
Anticholinergic bronchodilators
CountryIpratropium bromideOxitropium Bromide
AustriaXX
BelgiumXX
CyprusXX
Czech RepublicXX
DenmarkXX
EstoniaXX
FinlandXX
France
GermanyXX
GreeceXX
HungaryXX
IrelandXX
Italy
LatviaXX
LithuaniaXX
LuxembourgXX
MaltaXX
NetherlandsXX
Poland
PortugalX
Norway
SlovakiaXX
SloveniaXX
SpainXX
SwedenXX
United KingdomXX
Table 5
Long acting beta agonist bronchodilators
CountryFormoterolSalmeterol
AustriaXX
BelgiumXX
CyprusX
Czech RepublicXX
Denmark
EstoniaXX
FinlandXX
FranceXX
GermanyXX
Greece
HungaryXX
IrelandXX
ItalyXX
LatviaXX
LithuaniaXX
LuxembourgXX
MaltaXX
NetherlandsX
Poland
Portugal
Norway
SlovakiaXX
SloveniaXX
SpainX
SwedenXX
United Kingdom
Table 6
Combinations of active ingredients in a single MDI
Country
AustriaX All products
BelgiumX All products
Cyprus
Czech RepublicX All products
Denmark
Estonia
FinlandX All products
FranceX All products
GermanyX All products
Greece
HungaryX All products
Ireland
ItalyBudesonide + FenoterolFluticasone + Salmeterol
LatviaX All products
LithuaniaX All products
LuxembourgX All products
MaltaX All products
Netherlands
Poland
Portugal
Norway
SlovakiaX All products
SloveniaX All products
Spain
SwedenX All products
United Kingdom
  1. Division